Evaluation of repeated clinical dose of rocuronium after reversal of neuromuscular block by sugammadex within a short time in re-surgical patients.

Evaluation of repeated clinical dose of rocuronium after reversal of neuromuscular block by sugammadex within a short time in re-surgical patients. - Evaluation of repeated clinical dose of rocuronium after reversal of neuromuscular block by sugammadex within a short time in re-surgical patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007647

Enrollment

Registered

2012-05-01

Start date

2012-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients who required re-surgery within a short time after using sugammadex.

Interventions

Patients who required re-surgery within 12hours after neuromuscular block reversal by Sugammadex.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who required re-surgery within 12hours after neuromuscular block reversal by Sugammadex.

Exclusion criteria

Exclusion criteria: patients with full stomach or with difficult airway.

Design outcomes

Primary

Measure	Time frame
Time from administration of second Rocuronium to maximum depression of T1 height at the re-surgery.	—

Countries

Japan

Contacts

Public ContactHajime Iwasaki

Asahikawa Medical University Anesthesiology and Critical Care Medicine

iwasakih@asahikawa-med.ac.jp0166-65-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026